Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2018 ASCO Annual Meeting /
ASCO 2018: Latest in bladder cancer treatments

1st - 5th Jun 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.06.18
Views: 2885

Prof Thomas Powles & Prof Shahrokh Shariat

Prof Thomas Powles (Barts Cancer institute, London) and Prof Shahrokh F. Shariat (Vienna General Hospital, Austria) meet at ASCO 2018 to discuss the current patient eligibility changes within immuno-oncology following new guidance from EMA/FDA and share their thoughts on emerging neoadjuvant data with checkpoint inhibitors following some investigator initiated trials.

Both experts share their views on recently presented data on IDO1 inhibitors and pan-FGFR kinase inhibitors and signpost that future management of urothelial cancers front line may involve combination of therapies of PDL-1 with PARP or CTLA-4 inhibitors.

Atezolizumab and pembrolizumab in platinum refractory bladder cancer
Prospects for CTLA4 and IDO combinations
FGFR inhibitors in clinical trials
Upcoming combinations for bladder cancer
Adjuvant and neoadjuvant therapies

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation